美国联合医疗 UTHR 深 沪
等待开盘 08-19 09:30:00 美东时间
518.27
+9.790
+1.93%
华盛通- 最 高519.21
- 今 开510.42
- 成交量 36.64万股
- 最 低 508.56
- 昨 收 508.48
- 总市值 222.29亿
- 52周最高 609.35
- 市盈率 静 18.60
- 换手率 0.85%
- 52周最低 375.61
- 委 比 57.14%
- 总股本 4289.07万
- 历史最高 609.35
- 量 比 0.91
- 振 幅 2.09%
- 历史最低 36.55
- 每 手 1
- 风险率 64.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Quant ratings on Renaissance Technologies top holdings: NVDA, META, INTC
Renaissance Technologies, founded by Jim Simons, made several changes to its holdings between Q1 and Q2 2026. The quantitative investment firm outperformed the S&P 500 in Q2, returning 33.19% compared...
08-18 02:10
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment options Topline data expected in the second half of 2027 United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (treprostinil) inhalation soluti...
08-17 19:11
Beta Technologies shares fall on deeper-than-expected loss
Beta Technologies (BETA) shares fell 4% in premarket trading Wednesday after the electric-aircraft maker reported a wider-than-expected second-quarter loss, overshadowing revenue that topped Wall Stre...
08-12 20:18
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Liquidia Corporation reported strong financial results for Q2 2026, with YUTREPIA sales reaching $170.4 million, up 31% from Q1 2026. The company achieved net income of $74.7 million and adjusted EBITDA of $96.3 million, marking the fourth consecutive quarter of increasing profitability. Since its launch in June 2025, YUTREPIA has been prescribed to approximately 5,900 unique patients, with over 5,000 treated. Liquidia is advancing 10 clinical st...
08-12 10:30
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.
08-07 01:57
MannKind 2026年第二季度财报：营收增43%，费用扩张转为亏损
MannKind 2026年第二季度营收1.094亿美元，同比增长43%，稀释每股亏损0.06美元、净亏损1903万美元；Furoscix与合作收入推动增长，但商业化及融资成本加重亏损。
08-05 21:17
财报速睇 | 美国联合医疗 2026财年Q2营收7.83亿美元，同比下降2.0%；归母净利润3.33亿美元，同比增长7.4%
华盛资讯8月5日讯，美国联合医疗公布2026财年Q2业绩，公司Q2营收7.83亿美元，同比下降2.0%，归母净利润3.33亿美元，同比增长7.4%。
08-05 18:57
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.
07-24 02:47
